RELAX-AHF Mortality Prediction Score Calculator

RELAX-AHF Mortality Prediction Score: Explanation and Clinical Context The RELAX-AHF (Relaxin in Acute Heart Failure) Mortality Prediction Score was developed from the RELAX-AHF trial to estimate the risk of all-cause mortality in patients with acute decompensated heart failure. This tool combines routine clinical variables available at admission to provide individualized risk estimates. Key predictors include age, blood pressure, renal function (BUN, creatinine), serum sodium, hemoglobin, uric acid, heart rate, and comorbidities such as ischemic heart disease and diabetes.

These variables reflect the severity of cardiac dysfunction, hemodynamic compromise, and multi-organ involvement. The score was derived from logistic regression analysis of the RELAX-AHF trial dataset, which evaluated serelaxin in acute heart failure. The model showed good discrimination for short- and medium-term mortality (up to 180 days) and can be used for bedside risk stratification, clinical decision-making, and identifying high-risk patients who may benefit from closer monitoring or advanced therapies.

Clinical Interpretation Summary: - Low Risk: <5% predicted mortality — good prognosis with standard therapy. - Intermediate Risk: 5–15% predicted mortality — consider optimization of therapy and follow-up. - High Risk: >15% predicted mortality — requires intensive management and possibly advanced heart failure evaluation.